Omnicell, Inc. (OMCL) - Q1 2026 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended March 31, 2026. Omnicell, Inc. is a leading healthcare technology provider focused on medication management solutions, including automated dispensing systems, software, and consumables. The company operates as a single reportable segment serving the healthcare industry, primarily in the United States.
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 | Change |
|---|---|---|---|
| Total Revenues | $309.9 million | $269.7 million | +15% |
| Gross Profit | $140.4 million | $110.9 million | +27% |
| Gross Margin | 45.3% | 41.1% | +420 bps |
| Operating Income | $16.9 million | ($11.6 million) | Turnaround to Profit |
| Net Income | $11.4 million | ($7.0 million) | Turnaround to Profit |
| Diluted EPS | $0.25 | ($0.15) | N/A |
| Operating Cash Flow | $54.5 million | $25.9 million | +110% |
| Cash & Equivalents | $239.2 million | $196.5 million | +22% |
| Convertible Debt (Net) | $167.9 million | $167.6 million | Minimal Change |
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased by $40.2 million (15%). Product revenue grew 20% to $174.8 million, driven by automated dispensing systems and XTExtend offerings. Service revenue grew 8% to $135.1 million, aided by technical services and SaaS/Expert Services.
- Profitability Turnaround: The company returned to profitability, reporting $11.4 million in net income compared to a $7.0 million net loss in Q1 2025. Operating income improved from a $11.6 million loss to a $16.9 million profit.
- Margin Expansion: Gross margin expanded to 45.3% from 41.1%, attributed to scale efficiencies, favorable product mix, and the absence of non-recurring software upgrade costs incurred in the prior year.
- Debt Structure: The 0.25% Convertible Senior Notes due 2025 matured in September 2025. The company currently holds $172.5 million in 1.00% Convertible Senior Notes due 2029. The $350 million revolving credit facility remains undrawn.
- Working Capital: Accounts receivable increased by $33.3 million due to timing of billings, while deferred revenues increased by $40.3 million, indicating strong future revenue visibility.
Outlook, Risks, and Commentary
- Management Commentary: Management highlights the "Autonomous Pharmacy" vision as a key growth driver. They note that fiscal headwinds in healthcare, including the "One Big Beautiful Bill Act" (OBBBA) and labor shortages, are driving demand for automation and flexible payment models (leasing/subscriptions).
- Tariff Impact: The company faces tariff headwinds from U.S. trade policies (Section 122 of the Trade Act of 1974). While mitigation strategies like dual-sourcing are in place, future cost impacts remain uncertain. A potential refund for previously paid IEEPA tariffs is pending but not yet recorded.
- Risks: Key risks include geopolitical instability, supply chain disruptions, cybersecurity threats, and the ability to maintain service levels for SaaS offerings. The company also faces risks related to changes in the 340B Drug Pricing Program and government regulations.
- Guidance: The filing does not contain specific numerical financial guidance for the full year 2026, though management expects continued growth in recurring revenue streams.
Investor Verification Checklist
- Deferred Revenue Quality: Verify the composition of the $40.3 million increase in deferred revenues to ensure it aligns with expected recognition timelines.
- Tariff Mitigation: Assess the effectiveness of dual-sourcing and nearshoring strategies in offsetting the new 10% Section 122 tariffs.
- Debt Conversion Risk: Monitor the stock price relative to the $57.25 conversion price of the 2029 Notes to evaluate potential dilution or cash settlement obligations.
- Customer Concentration: Confirm that no single customer exceeds 10% of revenue, as stated, and review the impact of GPO fee structures on net revenue.
- Capital Expenditures: Review the $12.4 million in CapEx for Q1 2026 to ensure alignment with the company's growth strategy and cash flow generation.